Table 1 Demographic characteristics, asthma status and treatment at screening
Fluticasone/formoterol | Fluticasone/salmeterol | |
|---|---|---|
(N = 101) | (N = 101) | |
Age (years) | ||
Mean ± SD | 47.6 ± 12.6 | 46.0 ± 12.9 |
Median (range) | 50.0 (18–75) | 47.0 (18–76) |
Gender | ||
Male, n (%) | 47 (46.5) | 39 (38.6) |
Female, n (%) | 54 (53.5) | 62 (61.4) |
Race | ||
Caucasian, n (%) | 101 (100.0) | 101 (100.0) |
Weight (kg), mean ± SD | 79.0 ± 15.3 | 76.1 ± 16.3 |
Height (cm), mean ± SD | 170.2 ± 9.9 | 167.6 ± 8.4 |
BMI (kg/m 2 ), mean ± SD | 27.3 ± 4.8 | 27.1 ± 5.3 |
FEV 1 pre-salbutamol (L), mean ± SD | 2.11 ± 0.56 | 2.11 ± 0.52 |
FEV 1 post-salbutamol (L), mean ± SD | 2.70 ± 0.79 | 2.63 ± 0.66 |
Predicted FEV 1 (L), mean ± SD | 3.20 ± 0.73 | 3.08 ± 0.65 |
FEV 1 % predicted, mean ± SD (range) | 66.1 ± 10.1 (41–85) | 68.6 ± 9.2 (44–85) |
FEV 1 reversibility (%), mean ± SD | 27.6 ± 12.8 | 24.9 ± 9.9 |
Treatment | ||
ICS, n (%) | 93 (92.1) | 94 (93.1) |
ICS dose (μg), median (range)* | 500 (100–1000) | 400 (100–1000) |
LABA, n (%) | 78 (77.2) | 78 (77.2) |